Skip to content

Partnership in prostate cancer care

Partnership in Prostate Cancer Care: the feasibility of an integrated system to improve patient outcomes and experience (the ICARE-P Study)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN31380482
Enrollment
200
Registered
2017-01-09
Start date
2017-02-02
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Specialty: Primary Care, Primary sub-specialty: Cancer

Interventions

Intervention group: Intervention practices are recruited on the basis of their being willing to send practice nurses for Macmillan Cancer follow up training and the additional prostate specific traini

Sponsors

NHS Birmingham South and Central CCG
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Confirmed diagnosis of prostate cancer and are at any stage of the care pathway 2. Under any treatment regime 3. Diagnosed and/or treated at University Hospitals Birmingham (UHB) or are currently undergoing treatment at UHB 4. Able to read written and comprehend spoken English and complete outcome measures 5. Judged by their GP to have the capacity to participate 6. Aged 18 years or over 7. Able and willing to give informed consent

Exclusion criteria

Exclusion criteria: 1. Aged under 18 years 2. Unable to give informed consent or complete outcome measures 3. Living in a care setting, suffering from severe mental health problems or unable to communicate in English

Design outcomes

Primary

MeasureTime frame
Feasibility is assessed through recording the the percentage of eligible men recruited and the percentage of men who complete the Holistic Needs assessments at baseline, 6 and 9 months

Secondary

MeasureTime frame
1. Cancer survivors' supportive care needs will be assessed using the cancer survivors unmet needs survey (CASUN) at baseline, 6 and 9 months 2. Quality of life will be measured using the EORTC QLQ-C30 at baseline and 9 months 3. Quality adjusted life years will be measured using the EQ-5D-5L at baseline and 9 months 4. Mental wellbeing will be measured using the Warwick and Edinburgh Mental Well-being scale (WEMWBS) at baseline and 9 months 5. Prostate specific concerns will be measured using EPIC at baseline and 9 months 6. Participant engagement in their healthcare will be measured using the Patient Activation measure (PAM) at baseline 3 and 9 months

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 26, 2026